Sheth AN, Angert CD, Haddad LB, et al. - Researchers investigated women with HIV initiating antiretroviral therapy (ART) in a US clinical trial for determining contraception and dual method use among these women. In addition, they sought the associated factors. Analysis was performed on data from ART-naïve women aged 45 years and under who started one of 3 regimens as part of A5257 (May 2009–June 2011) which required that women at risk for pregnancy use contraception. Among 285 assessed women, permanent contraception (37%), male condoms alone (31%), and injectable progestin (8%) were the most common contraceptive methods reported at baseline; 41% and 16% reported Tier 1 and 2 use, respectively; 36% reported dual method use. In multivariable analyses, they identified age at least 40 years vs 18 to 29 years and having at least one child to be associated with baseline use of more effective and dual methods. Based on findings, they emphasize the necessity for making efforts to improve integration of family planning services for women within the context of HIV clinical trials.